The decision of the FDA allows the product to be sold in the US, where it is patent protected until 2017. Nycomed is in active negotiations with possible marketing partners for the commercialization of Alvesco in the US.
Alvesco (ciclesonide) inhalation aerosol is a new generation of inhaled corticosteroid that reduces inflammatory processes and is indicated for the use in patients with asthma.
Myron Zitt, chief of allergy and immunology at the Queens Long Island Medical Group in Babylon, New York, said: “The approval of Alvesco provides a new and effective treatment option to help patients control their asthma and improve their quality of life, and will be an important treatment option for physicians.”